AG
OCUL icon

Algert Global’s Ocular Therapeutix OCUL Stock Holding History

Algert Global’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.82M Buy
592,309
+53,370
+10% +$484K 0.07% 467
2026
Q1 		$4.56M Buy
538,939
+411,529
+323% +$3.92M 0.07% 467
2025
Q4 		$1.55M Buy
+127,410
New +$1.55M 0.02% 767
2025
Q2 		– Sell
-29,020
Closed -$213K – 1299
2025
Q1 		$213K Buy
+29,020
New +$223K 0.01% 1075
2024
Q3 		– Sell
-10,114
Closed -$69.2K – 1459
2024
Q2 		$69.2K Buy
+10,114
New +$62.4K ﹤0.01% 1429
2023
Q4 		– Sell
-25,480
Closed -$80K – 1220
2023
Q3 		$80K Sell
25,480
-23,750
-48% -$97.2K ﹤0.01% 1046
2023
Q2 		$254K Buy
+49,230
New +$293K 0.01% 940
2022
Q4 		– Sell
-73,590
Closed -$305K – 1235
2022
Q3 		$305K Buy
73,590
+5,310
+8% +$26.7K 0.02% 945
2022
Q2 		$274K Buy
68,280
+56,423
+476% +$213K 0.02% 942
2022
Q1 		$59K Buy
+11,857
New +$65.7K ﹤0.01% 1134
2021
Q4 		– Sell
-10,100
Closed -$101K – 1066
2021
Q3 		$101K Buy
+10,100
New +$113K 0.01% 966

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Algert Global's OCUL Position: Q2 2026 in Review

Algert Global increased its Ocular Therapeutix (OCUL) stake by 9.9% in Q2 2026, buying an estimated $484K and bringing the position to 592,309 shares worth $5.82M. The position accounts for 0.07% of the portfolio, ranked #467.

Algert Global first reported a position in OCUL in Q3 2021 and has held it in 11 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Algert Global held 592,309 shares of Ocular Therapeutix worth $5.82M as of Q2 2026.
  • Algert Global bought 53,370 Ocular Therapeutix shares in Q2 2026, an estimated $484K.
  • Ocular Therapeutix made up 0.07% of Algert Global's portfolio in Q2 2026, its #467 holding.
  • Algert Global first reported a position in Ocular Therapeutix in Q3 2021 and has held it in 11 quarters since.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.